A feature in New Hope Network reports that the collapsing boundary between peptide drugs, compounded prescriptions and dietary supplements is the biggest regulatory moment the supplement industry has faced in decades. Industry advisor Loren Israelsen, who helped craft DSHEA in 1994 and watched the ephedra ban and the CBD collapse, told the outlet the peptide moment is "pacing to be the largest" and also "the foggiest."
The confusion starts with the word itself. "Peptide" now covers FDA-approved drugs such as the GLP-1s, patient-specific compounded medications, unapproved gray-market injectables like BPC-157 and TB-500, and decades-old supplement ingredients including collagen and milk-derived peptides.
How the rules moved
In April, 12 gray-market peptides came off the FDA's do-not-compound list, leaving them in what the piece calls regulatory purgatory. Three months later the agency's Pharmacy Compounding Advisory Committee voted to recommend six of seven peptides, including BPC-157 and TB-500, for compounding access, going against the recommendations of FDA's own scientists.
In October, FDA and the federal health department announced steps to revise compounding policy for peptide drugs. Legal experts quoted in the article expect a contested process, with comment periods and litigation, following the pattern set by the GLP-1 shortage determinations in 2022 and 2023.
Research chemicals with a Supplement Facts panel
The sharper problem is products sold as supplements that contain injectable research peptides. Michael Levin of Health Business Strategies is blunt about it: "It's illegal. Hard stop," he says, describing brands buying research chemicals that are unlawful in a dietary supplement.
Ashish Talati of Talati Law Firm makes the same point: calling an unapproved drug a supplement, a research chemical or RUO does not change what it is. Oliver Catlin of BSCG warns the harm runs past reputation into category collapse, since every exception chips at what the word supplement is supposed to mean.
Who actually loses
The weight management shelf is the cautionary tale. SPINS data cited in the piece shows weight-loss supplements declining at a low-double-digit rate, on top of an 11.9% drop reported at Expo West 2025, while 21% of households now include a GLP-1 user and 80% of those users take a companion supplement.
Bottom line
Israelsen's suggested route is the helper role rather than the headline ingredient, and Jacques argues a rising tide lifts all peptide categories. Neither outcome is settled until FDA says what its revised compounding policy actually is.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.